Charles Patrick Davis, MD, PhD
Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
- What is multiple myeloma?
- What causes multiple myeloma?
- What are risk factors for multiple myeloma?
- What are the signs and symptoms of multiple myeloma?
- How is multiple myeloma diagnosed?
- What are the stages of multiple myeloma?
- What is the treatment for multiple myeloma?
- What is the prognosis for multiple myeloma?
- What support systems are available for multiple myeloma?
- Patient Comments: Multiple Myeloma - Symptoms
- Patient Comments: Multiple Myeloma - Prognosis
- Patient Comments: Multiple Myeloma - Diagnosis
- Patient Comments: Multiple Myeloma - Treatment
- Find a local Oncologist in your town
What is multiple myeloma?
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The special proteins are typically monoclonal paraprotein (M protein) and other compounds such as immunoglobulins. Plasma cells are white blood cells that make antibodies and are part of the body's immune system. Multiple myeloma plasma cell proliferation can result in etched away bone (lytic bone lesions), soft tissue masses, impaired immune system, and pain from collapsing bone and other systemic problems listed below.
What causes multiple myeloma?
What triggers plasma cells to become malignant in multiple myeloma is not known. The cancerous myeloma plasma cells proliferate and crowd out normal plasma cells and can etch away areas of bones. The proteins produced in large amounts can cause many of the symptoms of the disease by making the blood more thickened (viscous) and depositing the proteins in organs that can interfere with the functions of the kidneys, nerves, and immune system.
What are risk factors for multiple myeloma?
The definitive cause of multiple myeloma has not been established but research has suggested several factors may be risk factors or contribute to multiple myeloma development in an individual. A genetic abnormality such as c-Myc oncogenes and others have been associated with multiple myeloma development. Currently, there is no evidence that heredity plays a role in multiple myeloma development. Environmental exposures to herbicides, insecticides, benzene, hair dyes, and radiation have been suggested as causes but definitive data is lacking. Inflammation and infection have been suggested but again not proven to cause multiple myeloma. However, a "benign" proliferation of a plasma cell can result in a situation where a monoclonal antibody is produced in high amounts (but not as high as seen with multiple myeloma). This result is termed monoclonal gammopathy of unknown or undetermined significance (abbreviated as MGUS). About 19% of MGUS patients develop multiple myeloma in about 2 to 19 years after MGUS diagnosis. In addition, about 7% of multiple myeloma patients develop MGUS within a year of developing multiple myeloma (this particular form of MGUS is termed secondary MGUS). Some researchers think MGUS antibody may result from as yet undetermined sources of inflammation or infection.
Viewers share their comments
- Submit »
Get the latest treatment options.